Acrivon's ACR-368 for ovarian, uterus cancers gets FDA fast track designations
hapabapa
- The U.S. Food and Drug Administration (FDA) granted two fast track designations to Acrivon Therapeutics' (NASDAQ:ACRV) to develop ACR-368 to treat platinum-resistant ovarian and endometrial cancers.
- One fast track status was granted for ACR-368 (also known as prexasertib) as a monotherapy for patients with OncoSignature positive, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian cancer who have received at least one prior systemic therapy regimen.
- The second fast track designation was granted for ACR-368 as a monotherapy for patients with OncoSignature positive, recurrent high-grade endometrial cancer who have received at least two prior systemic therapy regimens.
- Endometrial cancer starts in the layer of cells which form the lining (endometrium) of the uterus.